Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Aurinia Pharmaceuticals by 1,289.3% in Q1, acquiring an additional 72,240 shares, bringing its total holdings to 77,843 shares valued at approximately $626,000.
• Director Kevin Tang purchased 1,000,000 shares of Aurinia Pharmaceuticals for about $10.12 per share, resulting in an ownership increase of 9.97% and bringing his total ownership to approximately $111.6 million.
• Aurinia Pharmaceuticals reported $0.16 earnings per share for the last quarter, missing estimates, while revenue reached $70.01 million, surpassing projections.

Russell Investments Group Ltd. raised its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 1,289.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,843 shares of the biotechnology company's stock after buying an additional 72,240 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of Aurinia Pharmaceuticals worth $626,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC boosted its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $31,000. GAMMA Investing LLC increased its stake in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the last quarter. Finally, USA Financial Formulas purchased a new position in Aurinia Pharmaceuticals during the first quarter worth about $50,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Aurinia Pharmaceuticals

In related news, Director Kevin Tang bought 1,000,000 shares of the stock in a transaction dated Friday, August 1st. The stock was acquired at an average price of $10.12 per share, for a total transaction of $10,120,000.00. Following the completion of the purchase, the director owned 11,029,500 shares in the company, valued at $111,618,540. This represents a 9.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought a total of 1,300,000 shares of company stock worth $13,590,000 in the last 90 days. Insiders own 12.20% of the company's stock.

Wall Street Analysts Forecast Growth

AUPH has been the subject of several recent analyst reports. Royal Bank Of Canada lifted their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $12.00.

Aurinia Pharmaceuticals Trading Up 1.8%

NASDAQ AUPH traded up $0.21 during mid-day trading on Wednesday, hitting $11.89. The company's stock had a trading volume of 1,097,913 shares, compared to its average volume of 1,620,603. The firm has a market capitalization of $1.56 billion, a P/E ratio of 27.64 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals Inc has a 52-week low of $6.42 and a 52-week high of $12.53. The stock's fifty day simple moving average is $10.05 and its two-hundred day simple moving average is $8.73.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.